Despite we did the analysis in our “validation cohort” at baseline and at 12 weeks of treatment, it should also be noted that a better analysis would be a longitudinal analysis with multiple measures that could evaluate the Cyr61 level and its correlation with RA disease activity dynamically. Here, CCN1 is linked to rheumatoid arthritis.